1. Repositório Aberto da Universidade do Porto
  2. I3S - Instituto de Investigação e Inovação em Saúde
  3. I3S - Artigo em Revista Científica Internacional
Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143534
Full metadata record
DC FieldValueLanguage
dc.creatorTaheri, Y
dc.creatorSuleria, HAR
dc.creatorMartins, N
dc.creatorSytar, O
dc.creatorBeyatli, A
dc.creatorYeskaliyeva, B
dc.creatorSeitimova, G
dc.creatorSalehi, B
dc.creatorSemwal, P
dc.creatorPainuli, S
dc.creatorKumar, A
dc.creatorAzzini, E
dc.creatorMartorell, M
dc.creatorSetzer, WN
dc.creatorMaroyi, A
dc.creatorSharifi-Rad, J
dc.date.accessioned2022-08-29T14:35:33Z-
dc.date.available2022-08-29T14:35:33Z-
dc.date.issued2020
dc.identifier.issn2662-7671
dc.identifier.urihttps://hdl.handle.net/10216/143534-
dc.description.abstractSeveral flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.
dc.description.sponsorshipThis work was partially supported by CONICYT PIA/APOYO CCTE AFB170007. N. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the Strategic project ref. UID/BIM/04293/2013 and “NORTE2020 - Northern Regional Operational Program” (NORTE-01-0145- FEDER-000012).
dc.language.isoeng
dc.publisherBMC
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FBIM%2F04293%2F2013/PT
dc.relation.ispartofBMC Complementary Medicine and Therapies, vol.20(1):241
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/
dc.subjectAntimicrobial
dc.subjectAntioxidant
dc.subjectCancer
dc.subjectCardiovascular disease
dc.subjectDiabetes
dc.subjectImmunomodulatory
dc.subjectMyricetin
dc.subjectNeuroprotection
dc.subject.meshAnti-Infective Agents / chemistry
dc.subject.meshAnti-Infective Agents / pharmacology
dc.subject.meshAntineoplastic Agents / chemistry
dc.subject.meshAntineoplastic Agents / pharmacology
dc.subject.meshAntioxidants / chemistry
dc.subject.meshAntioxidants / pharmacology
dc.subject.meshDietary Supplements
dc.subject.meshFlavonoids / chemistry
dc.subject.meshFlavonoids / pharmacology
dc.subject.meshHumans
dc.subject.meshHypoglycemic Agents / chemistry
dc.subject.meshHypoglycemic Agents / pharmacology
dc.subject.meshMolecular Structure
dc.subject.meshNeuroprotective Agents / chemistry
dc.subject.meshNeuroprotective Agents / pharmacology
dc.titleMyricetin bioactive effects: Moving from preclinical evidence to potential clinical applications
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1186/s12906-020-03033-z
dc.relation.publisherversionhttps://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-020-03033-z
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1186-s12906-020-03033-z.pdf897.03 kBAdobe PDFThumbnail
View/Open
Show simple item record Recommend this item Display Statistics


This item is licensed under a Creative Commons License Creative Commons